Winston-Salem, N.C., June 6, 2024 – KeraNetics, the maker of KeraStat® Cream, which is one of the only FDA-cleared products for radiation dermatitis, was selected as a contributor to the Advanced Technological Education (ATE) Impacts program and the video is now available. This initiative, which includes the production of a compelling book and blog, aims to spotlight the profound influence of ATE funding. KeraNetics involvement within this program extends to a video designed to chronicle the personal journeys of individuals touched by these funds and illustrate how their stories intersect.

KeraNetics’ manufacturing team, along with CEO, Dr. Luke Burnett, are prominently featured, offering a firsthand account of how the private sector thrives on ATE funding. The ATE, a subsidiary of the National Science Foundation (NSF), has been a pillar of support for advanced technology education for three decades. Their dedication is reflected in funding initiatives that propel education in biotechnology and other cutting-edge industries, bridging the gap between community colleges and employers. By ensuring up-to-date curricula and providing financial support to students pursuing associate degrees in technology, ATE plays a crucial role in shaping the future of the workforce.

“Dissemination of the ATE Impacts book will advance understanding of the importance of technicians to the vitality of high-tech industries that drive the economy. By highlighting the successful, innovative work of ATE centers and projects, the book will encourage broader participation in the ATE program by academic institutions, educators, and industry partners.” (“ATE Impacts video.” ATE Impacts, Nov. 17 2023,

“Our excitement to contribute to this initiative is magnified by the prospect of highlighting how KeraNetics, and other biotechnology startups, have revitalized what was an undesirable downtown environment in Winston-Salem, North Carolina, just a decade ago. Proudly incorporated in North Carolina and headquartered in Winston-Salem’s Innovation Quarter, we are eager to share our story, our dedicated employees, and our community engagement,” said Dr. Luke Burnett, CEO. “More specifically, our product is one that has not only helped a community but has changed the lives of patients receiving radiotherapy for head, neck, throat, skin and breast cancers.”

You can check out our contribution to this insightful exploration of the transformative power of ATE funding by viewing the Forsyth Tech / KeraNetics video here.

About KeraNetics
KeraNetics is a biotechnology company dedicated to the development of keratin-based products to manage complex battlefield injuries and improve the quality of life for cancer patients experiencing radiation dermatitis. Since its founding in 2008, KeraNetics has worked with government agencies including the Department of Defense (DoD), the Biomedical Advanced Research and Development Authority (BARDA), and the Food and Drug Administration (FDA) to enhance the therapy options for battlefield and civilian wound care.

The KeraNetics team has decades of experience in creating, testing, and manufacturing FDA-regulated wound care products and is headquartered in the Innovation Quarter of downtown Winston-Salem, NC.